A leading Russian pharmaceutical company appointed GCT as the CRO of choice for managing their government-sponsored program aimed at bringing a generic inhalational anaesthetic to the local market.

This Phase III multi-center double-blind study is to be conducted in patients undergoing abdominal surgery and is currently in final stages of the Ministry of Health review.

GCT team has already completed the challenging task of site selection which fulfil regulatory and protocol requirements and are able to comply with the enrollment goal of 120 patients in time-conscious circumstances.  Apart from this, our staff is responsible for overall project management, LEC submissions, contracting support, clinical monitoring, safety reporting, data management, biostatistics and final report preparation.